Optic Nerve Disorders Treatment Market Opportunities, Drivers, Restraints, Threats, Trends, Applications And Growth Forecast To 2019-2027

                                                                            

  Optic Nerve Disorders Treatment Market

The second cranial nerve is the optic nerve of the eye, which aids in the transmission of sensory information to the brain for vision. During foetal development, this nerve develops from the optic vesicle of the forebrain. Loss of vision may result from damage to the optic nerve or its pathways to the brain. Various types of optic nerve disorders, such as glaucoma, optic nerve atrophy, optic neuritis, and optic nerve head drusen, are common throughout the glove. The majority of these disorders are treated symptomatically. The treatments may not improve vision, but they can help prevent vision loss as the disorder progresses.

The rising prevalence of various eye disorders caused by optic nerve damage is a major factor driving the growth of the Optic Nerve Disorders Treatment Market. The ageing population, which is more prone to ophthalmic problems such as low vision, is also a major factor driving the growth of the optic nerve disorders treatment market. According to the National Institutes of Health, the population of people aged 65 and up in the United States is expected to nearly double over the next three decades, rising from 48 million to 88 million by 2050. Furthermore, the high adoption rate of digital devices is fueling the growth of the optic nerve disorders treatment market due to the negative impact on vision.

Furthermore, the increasing prevalence of eye disorders in the region is expected to drive growth in the optic nerve disorders treatment market. According to the American Academy of Ophthalmology, approximately 7.32 million people are expected to suffer from primary open-angle glaucoma (POAG) in 2019, with the highest number among populations aged 70 to 79 years (32 percent), women (50 percent), and Hispanics (50 percent ).

Market Segmentation:

By drug class

• Steroids

• Analgesics

• Parasympathomimetics

• Beta-blockers & Alpha-adrenergic Agonists

• Carbonic Anhydrase Inhibitors

• Others

By distribution channel

• Hospital Pharmacies

• Clinics

• Retail Pharmacies

• Online Pharmacies

The key players operating in the global optic nerve disorder treatment market include Santen Pharmaceutical Co., Ltd., Allergan plc, Novartis International AG, Pfizer, Inc., Bausch Health Companies, Inc., Aerie Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bionure Farma, S.L., and Mallinckrodt Pharmaceuticals.